Collaboration, License and Other Arrangements (Tables)

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Credits Recognized in Condensed Consolidated Statements of Income

During the three months ended March 31, 2025 and 2024, the credits recognized in our condensed consolidated statements of income for CRISPR’s share of CRISPR JDCA activities were as follows:

	Three Months Ended March 31,
	2025		2024
	(in millions)
Cost of sales	$	36.2	$	15.8
Research and development expenses	$	16.0	$	11.7
Acquired in-process research and development expenses	$	12.5	$	—